The Glucagon-like peptide-1 (GLP1) drugs are set to be the star performers for insulin drug makers across the globe as the menace of diabetes and obesity is in line to rise exponentially in the years to come. GLP1 drugs are medications which have traditionally been used to treat type 2 diabetes and more recently for obesity. The pharma majors making GLP1 drugs globally are racing to get their drugs on the shelves with the demand for these drugs outstripping the supply in many markets. GLP1 drugs have become highly recommended due to their diverse treatment profile which is effective in lowering sugar levels, reducing obesity and providing cardiovascular risk benefits.We caught up with John C. Dawber, CVP and MD, Global Business Services, Novo Nordisk to know about the company’s growth story and much more.
Since your company is one of the leading drug makers in GLP1 medicines, how are you viewing the market growth rate here in India and globally?
Globally the GLP1 market was growing at a rate of 60 per cent in 2022 and we see it continuing to grow at a similar pace going forward. This has happened due to the benefits of these particular groups of medicines, which control blood glucose for people with diabetes and also reduce weight. And some of those molecules have evidence to show prevention of other complications of diabetes such as a heart attack and cardiovascular complications.
Bu hikaye BW Businessworld dergisinin August 12, 2023 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BW Businessworld dergisinin August 12, 2023 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
MEMORIES & IMPRESSIONS
Ratan Tata was an exceptional human being. He was a visionary leader, esteemed industrialist, and a humanitarian, who left an indelible mark on India and the world.
The Robotaxi Market
The robotaxi market is shaping up to be a high-stakes battleground as tech giants and automakers race to transform urban mobility.
And the Nobel Prize Goes to AI
The recent Nobel Prize T awards to AI pioneers affiliated with Google have sparked a broader conversation about Big Tech's influence on research and the limitations of traditional prize categories.
Ola Electrified
Once considered a trailblazer in India’s electric vehicle (EV) ecosystem, Bhavish Aggarwal’s Ola Electric now faces a major accountability crisis.
Sharp Slide in Industrial Output on Eve of Deepavali
India’s index of industrial production (IIP) saw a sharp reversal in August, contracting by 0.1 per cent, in stark contrast to the 4.7 per cent growth in July, mostly because of significant contractions in mining and electricity generation.
Heralding the Solar Era with Sustainable Electrification
RAJEEV KASHYAP on the economics of solar power, the hurdles in scaling it, and much more
A WELL-GREASED MACHINE
The OmniBook X14 laptop runs on first-generation Snapdragon X Elite, which bets big on Al-enabled productivity and battery life, but falls short when it comes to overall experience, says Deep Majumdar
DO NOT LETA HEALTH CRISIS RUIN YOUR FINANCIAL HEALTH
For a family of four living in a metro, it is recommended to opt for a family floater health insurance plan with a sum insured of at least Rs 15-20 lakh
Disruption Ahead: Beyond Organisation Charts and Structures
ALBERT EINSTEIN FAMOUSLY said, “We cannot solve our problems with the same thinking we used when we created them.
Dr. Rahul Shivajirao Kadam: A Visionary Leader Blending Sustainability, Innovation, And Social Empowerment
We are on the stage of global warming, and these technologies not only help prevent further damage but also leave behind a better environment for future generations.
